

**IN THE UNITED STATES PATENT  
AND TRADEMARK OFFICE**

This paper is being submitted  
via EFS-Web on

October 20, 2011

Serial. No. : 10/566,826  
Applicants : Akio KIMURA et al.  
Filed : January 31, 2006  
For : PROSTAGLANDIN-  
CONTAINING PRODUCT  
Art Unit : 1618  
Examiner : Jake Minh VU  
Docket No. : 06067/HG  
Confirm No. : 8012  
Customer No. : 01933

In the event that this Paper  
is late filed, and the  
necessary petition for  
extension of time is  
not filed concurrently  
herewith, please consider  
this as a Petition for the  
requisite extension of time,  
and to the extent not already  
paid, authorization to charge  
the extension fee to Account  
No. 06-1378. In addition,  
authorization is hereby given  
to charge any fees for which  
payment has not been submitted,  
or to credit any overpayments,  
to Account No. 06-1378.

**INFORMATION DISCLOSURE STATEMENT AND STATEMENT UNDER 37  
CFR 1.97(e)(2)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

S I R :

The enclosed IDS Form identifies documents (Baker et al. and CAS (entry  
RN9010-29-1, 2011)) that were cited in copending related application Serial No.  
11/792,637. A copy of the non-patent document identified on the enclosed IDS  
form is enclosed.

The following prior art rejection was set forth in the August 9, 2011 Office Action in copending related application Serial. No. 11/792,637:

“Claims 1 and 9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baker et al. (US Pub. 2005/0049311) in view of Fetz et al. (WO02/51452) and Kis et al. (WO0073156, provided by Applicant on the IDS dated 10/18/2010), as evidenced by CAS (entry for RN 9010-79-1, 2011).”

**STATEMENT UNDER 37 CFR 1.97(e)(2)**

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement.

The USPTO fee of \$180 is being paid by credit card herewith.

It is respectfully requested that an initialed copy of the enclosed IDS Form be returned to the undersigned to indicate that all the documents listed therein were considered and made of record.

Holtz, Holtz, Goodman  
& Chick PC  
220 Fifth Ave., 16th Floor  
New York, NY 10001-7708  
Tel. No.: (212) 319-4900  
Fax No.: (212) 319-5101

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Richard Barth", written over a horizontal line.

Richard S. Barth  
REG. NO. 28,180

E-Mail Address: [rbarth@hhpatent.com](mailto:rbarth@hhpatent.com)  
RSB/ean

Encs.